In multiple pre-clinical models of substance abuse and anxiety, ALDH2 inhibition prevents dopamine surge without changes to basal dopamine levels, and
ALDH2 Inhibition: Published Pre-Clinical Efficacy Data
ANS-6637 is a Phase-2 ready first-in-class compound that utilizes a novel pathway for the treatment of addiction.
ANS-6637 is highly selective ALDH2 Inhibitor that modifies dopaminergic tone by preventing pathophysiologic dopamine surges and associated craving without changes to basal dopamine. This profile, which prevents craving and drug seeking behavior, has the potential to be used as pharmacotherapy for substance and behavior and based addictions.
MOA published in Nature Medicine
ALDH2 inhibition prevents pathophysiologic dopamine surges and associated craving without changes to basal dopamine
ALDH2 Inhibition: Published Neurobiologic Model of Addiction and Mechanism of Action
Dopamine surge is common to all substance and behavioral addiction
“Environmental stimuli elicit surges of dopamine that trigger craving”